Why the study?
The study evaluated the effect of dapagliflozin therapy on myocardial remodeling and fibrosis assessed by contrast-enhanced cardiac MRI in patients with CHF and AF.
Does dapagliflozin therapy improve myocardial remodeling and fibrosis in patients with chronic heart failure and atrial fibrillation?
Does dapagliflozin therapy improve myocardial remodeling and fibrosis in patients with chronic heart failure and atrial fibrillation?
Dapagliflozin therapy over 6 months is associated with favorable myocardial remodeling, including increased LVEF and halted progression of fibrosis, in patients with HFrEF and AF.
AIM: To determine the effect of dapagliflozin therapy on myocardial remodeling and fibrosis according to magnetic resonance imaging (MRI) with contrast in patients with chronic heart failure (CHF) and atrial fibrillation (AF). MATERIALS AND METHODS: In the group of 22 patients with a combination of CHF and AF we analyzed the dynamics of remodeling parameters and assessed myocardial fibrosis during 6-month therapy with dapagliflozin according to cardiac MRI with contrast. RESULTS: After 6 months of dapagliflozin therapy there was a statistically significant increase in LVEF (27 [23-32]-32 [26.5-36.5] p-0.04) and a tendency to decrease volume and linear dimensions of LV, LP. There was no progression of myocardial fibrosis according to the results of cardiac MRI with contrast in patients with HFrFV and AF. CONCLUSIONS: Dapagliflozin therapy in patients with HFrEF and AF led to favorable myocardial remodeling changes.
No takes yet. Share an insight, caveat, or question.
Saipudinova et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: